Sugi Predict

Sugi Predict / Compounds / SCHEMBL1992431

SCHEMBL1992431

SCHEMBL1992431

CCCC(N[C@@H](C)C(=O)O)C(=O)OCC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 10/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ KMT2A Q03164 4/20 0.38
▸ POLB P06746 1/20 0.38
▸ ABCB11 O95342 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ AKR1A1 P14550 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR2C P28335 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4650239 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL300279 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL300278 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4400451 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL13482629 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4458272 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4458267 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
SCHEMBL4400447 1.00 ACE (0.49) ACEL3MBTL1LMNAKMT2APOLB
Hydrochloric Acid SCHEMBL5287673 0.98 ACE (0.48) ACEL3MBTL1LMNAKMT2APOLB
Hydrochloric Acid SCHEMBL3536442 0.98 ACE (0.48) ACEL3MBTL1LMNAKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2612851-B1 Process for the preparation of the L-arginine salt of perindopril SERVIER LAB (FR) 2016-07-06 — — EP claimed
US-8865915-B2 Process for the preparation of the L-arginine salt of perindopril LES LABORATOIRES SERVIER (FR) 2014-10-21 — — US claimed
US-20130178635-A1 PROCESS FOR THE PREPARATION OF THE L-ARGININE SALT OF PERINDOPRIL LES LABORATOIRES SERVIER (FR) 2013-07-11 — — US claimed
EP-2612851-A1 Process for the preparation of the L-arginine salt of perindopril Les Laboratoires Servier (FR) 2013-07-10 — — EP claimed
CN-103193863-B The preparation method of the L arginine salt of perindopril 瑟维尔实验室 2017-03-01 — — CN disclosed
EP-2612851-B1 Process for the preparation of the L-arginine salt of perindopril SERVIER LAB (FR) 2016-07-06 — — EP disclosed
US-8865915-B2 Process for the preparation of the L-arginine salt of perindopril LES LABORATOIRES SERVIER (FR) 2014-10-21 — — US disclosed
EP-2044010-B1 NEW PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INIHIBITORS AND THE USE THEREOF EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDO RESZVENYTARSASAG (HU) 2014-01-08 — — EP disclosed
US-20130178635-A1 PROCESS FOR THE PREPARATION OF THE L-ARGININE SALT OF PERINDOPRIL LES LABORATOIRES SERVIER (FR) 2013-07-11 — — US disclosed
EP-2612851-A1 Process for the preparation of the L-arginine salt of perindopril Les Laboratoires Servier (FR) 2013-07-10 — — EP disclosed
US-7960558-B2 Pharmaceutical intermediate for synthesizing ACE inhibitors and the use thereof EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2011-06-14 — — US disclosed
US-20100286404-A1 PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) 2010-11-11 — — US disclosed
WO-2003010142-A2 A PROCESS FOR THE PREPARATION OF PERINDOPRIL, ITS ANALGOUS COMPOUNDS AND SALTS THEREOF USING 2,5 -DIOXO-OXAZOLIDINE INTERMEDIATE COMPOUNDS ADIR (FR) 2003-02-06 — — WO disclosed
EP-1279665-A2 A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds ADIR (FR) 2003-01-29 — — EP disclosed
EP-0243645-B1 Compounds having a nootropic activity, agents containing them and their use in the treatment and prophylaxis of cognitive malfunctions HOECHST AG (DE) 1994-03-16 — — EP disclosed
US-5231084-A ACE inhibitor HOECHST AKTIENGESELLSCHAFT (DE) 1993-07-27 — — US disclosed
EP-0217519-B1 5-MEMBERED HETEROCYCLIC RING ANGIOTENSIN CONVERTING ENZYME INHIBITORS FISONS plc (GB) 1992-02-05 — — EP disclosed
US-4927822-A HYPOTENSIVE FISONS PLC (GB) 1990-05-22 — — US disclosed
EP-0243645-A2 Compounds having a nootropic activity, agents containing them and their use in the treatment and prophylaxis of cognitive malfunctions HOECHST AKTIENGESELLSCHAFT (DE) 1987-11-04 — — EP disclosed
EP-0217519-A1 5-membered heterocyclic ring angiotensin converting enzyme inhibitors FISONS plc (GB) 1987-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286404-A1 PHARMACEUTICAL INTERMEDIATES IN THE SYNTHESIS OF ACE-INHIBITORS AND THE USE THEREOF ACE, AGTR1, REN ACE 1/4885L3MBTL1 2820/4885LMNA 2592/4885
US-20130178635-A1 PROCESS FOR THE PREPARATION OF THE L-ARGININE SALT OF PERINDOPRIL REN, ARG1, ACE ACE 3/4885L3MBTL1 4018/4885LMNA 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.